Clinical trial
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
NCT04579757
Study timeline
Study start (actual)2021-03-05Date precision: day
Registry last updated2025-05-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Solid Tumorunresolved
Colorectal Cancerunresolved
Neuroendocrine Tumorsunresolved
Small Cell Lung Cancerunresolved
Gastric Cancerunresolved
Soft Tissue Sarcomaunresolved
Anaplastic Thyroid Cancerunresolved
Interventions
Sponsors & collaborators
Mapped research locations
DallasTexas, United States2NashvilleTennessee, United States2New YorkNew York, United States1HoustonTexas, United States1PhiladelphiaPennsylvania, United States1AtlantaGeorgia, United States1ClevelandOhio, United States1Washington D.C.District of Columbia, United States1DenverColorado, United States1TucsonArizona, United States1GreenvilleSouth Carolina, United States1Iowa CityIowa, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04579757 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.